Report #2853486

Overview

Sex

Female

Age

Age unknown

State

—

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (4)

Symptom narrative

pregnant patient received Arexvy instead of Abrysvo; pregnant patient received Arexvy instead of Abrysvo within the health system; pregnant patient received Arexvy instead of Abrysvo; This non-serious prospective pregnancy case was reported by a pharmacist via sales rep and described the occurrence of vaccine exposure during pregnancy in a adult female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Co-suspect products included RSV vaccine prot. subunit PreF 2v (Abrysvo) for prophylaxis. On an unknown date, the patient received Arexvy. The patient did not receive Abrysvo. On an unknown date, an unknown time after receiving Arexvy, the patient experienced vaccine exposure during pregnancy (Verbatim: pregnant patient received Arexvy instead of Abrysvo), wrong vaccine administered (Verbatim: pregnant patient received Arexvy instead of Abrysvo within the health system) and product use in unapproved population (Verbatim: pregnant patient received Arexvy instead of Abrysvo). The outcome of the vaccine exposure during pregnancy, wrong vaccine administered and product use in unapproved population were not applicable. Pregnancy exposure: Pregnancy Exposure (Arexvy): Trimester unknown Pregnancy Exposure (Abrysvo): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 28-JUL-2025 The pregnant patient received Arexvy instead of Abrysvo within the health system which led to wrong vaccine administered, product use in unapproved population and vaccine exposure during pregnancy. No negative outcomes apparent at the time of reporting provided.